Published in J Pathol on October 20, 2011
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol (2012) 1.78
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol (2014) 1.19
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun (2014) 1.05
A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care (Basel) (2013) 1.01
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. J Pathol (2015) 0.99
Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol (2011) 0.95
MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro Oncol (2012) 0.95
Adenoid cystic carcinoma of breast: Recent advances. World J Clin Cases (2014) 0.94
Uterine adenosarcomas are mesenchymal neoplasms. J Pathol (2015) 0.94
Genomic landscape of adenoid cystic carcinoma of the breast. J Pathol (2015) 0.93
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology (2013) 0.88
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol (2014) 0.87
Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology (2015) 0.83
Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. Histopathology (2015) 0.82
Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast (2015) 0.81
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist (2014) 0.80
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod Pathol (2016) 0.80
[Invasive breast cancer: the current WHO classification]. Pathologe (2014) 0.78
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Mod Pathol (2016) 0.78
The impact of the MYB-NFIB fusion proto-oncogene in vivo. Oncotarget (2016) 0.75
Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore) (2016) 0.75
Adenoid cystic carcinoma: emerging role of translocations and gene fusions. Oncotarget (2016) 0.75
The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers. Virchows Arch (2016) 0.75
Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. Virchows Arch (2015) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Triple-negative breast cancer. N Engl J Med (2010) 11.39
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst (2007) 4.46
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat (2009) 2.85
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A (2003) 2.64
Genetic interactions in cancer progression and treatment. Cell (2011) 2.54
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 2.35
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol (2011) 2.33
Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer (2004) 2.32
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
Sleep disturbances among soldiers with combat-related traumatic brain injury. Chest (2012) 2.13
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res (2007) 2.12
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 2.09
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2008) 2.06
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol (2007) 2.00
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 1.93
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Genetic heterogeneity and cancer drug resistance. Lancet Oncol (2012) 1.91
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med (2010) 1.90
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat (2007) 1.84
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83